Diabetes Care

Franklin Lakes, NJ, United States

Diabetes Care

Franklin Lakes, NJ, United States

Time filter

Source Type

— The research report titled “United States Blood Glucose Meter Market Insights, Opportunity, Analysis, Growth Potential & Forecast 2017 – 2022” examines the market, competitive landscape and trends of the United States Blood Glucose Meter Market. The study provides an in–depth analysis of the type 1, type 2 and newly diagnosed type 1 diabetes and overall diabetes population. Moreover, it also provides an essential insight on insulin users. Complete report on Blood Glucose Meter industry spread across 110 pages with providing 20 company Profiles, 20 tables and 14 figures is now available at http://www.marketreportsonline.com/587117.html Company Coverage of United States Blood Glucose Meter Market: Roche, LifeScan Inc, Abbott Diabetes Care, Arkray, Ascensia Diabetes Care, Fora Care, Entra Health, Fifty50 Medical, Infopia, Genesis Health Technologies, iHealth Labs, Oak Tree Health, Livongo Health, Nova Diabetes Care, Sanofi Diabetes, Telcare, Walgreens, U.S. Diagnostics, Prodigy Diabetes Care & Omnis Health Market growth can be attributed to factors such as increasing number of diabetic patients, growing awareness towards diabetes mellitus, improved glucose control and flexible, user–friendly design, government efforts for better management of diabetes mellitus and technological advancement in blood glucose meter devices. The report provides a decisive view on the Blood Glucose Meter Users and Market. It also covers reimbursement pattern and offers a clear view of the regulatory landscape in the United States Blood Glucose Meter Market. Key trends in terms of collaboration, partnership, distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States Blood Glucose Meter Market. The report concludes with the profiles of major players in the United States Blood Glucose Meter Market. The key market players are evaluated on various parameters such as company overview, marketed products and latest development and trends of the Blood Glucose Meter Market. United States Diabetes Population (2011 – 2022) Insulin Users (2011 – 2022) United States Blood Glucose Meter Users and Market Analysis (2011 – 2022) United States Blood Glucose Meter Market: Reimbursement & Regulation System United States Blood Glucose Meter Market – Major Deal Types Key Companies Analysis Key Drivers and Inhibitors of the United States Blood Glucose Meter Market Order a copy of this “Global Blood Glucose Meter Market” research report at USD 990 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=587117 4. Key Drivers and Inhibitors of the United States Blood Glucose Meter Market 4.1 Market Drivers 4.2 Inhibitors Europe Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) Market & Forecast: The incidence of diabetes mellitus is on the rise throughout Europe and its showing no signs of slowing down in the near future. Approximately 60 Million Europeans are living with diabetes today, including more than 90% with type 2 diabetes and this trend is on rise. At present Europe Blood Glucose Monitoring Device Market is more than USD 7 Billion. Russia, United Kingdom and Italy are top three dominating countries in the European Blood Glucose Monitoring Devices market in 2015. Russia market share is expected to decline whereas United Kingdom share is likely to rise by 2020. Germany, Spain and Italy holds significant market share in Europe market place. Global Glucose Monitoring Market with Focus on CGM: Industry Analysis & Outlook (2016-2020): Glucose monitoring helps people suffering from diabetes in managing their health and avoiding its associated problems. Any individual can use the results of glucose monitoring to make decisions about food, physical activity, and medications which can help him stay healthy. The most common glucose monitoring solutions are blood glucose meters and continuous glucose monitoring (CGM) systems. In addition to it, the traditional way to check glucose levels involves pricking a fingertip with an automatic piercing device to obtain a blood sample and then using a glucose meter to measure the blood sample's glucose level. Explore More Related Reports on Medical Devices Market at http://www.marketreportsonline.com/cat/medical-devices-market-research.html For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=587117


News Article | May 9, 2017
Site: www.prnewswire.com

"We are honored to be recognized by Forbes. It has always been our philosophy that if our physicians, nurses, entire medical staff and all of our other valued employees are happy and proud to work at NYU Winthrop, that this will translate into the highest quality medical care possible," said John Collins, President and CEO of NYU Winthrop. "We consider all who work at NYU Winthrop to be family, and this recognition underscores that the workplace environment that has long existed here has allowed each and every employee and medical professional to achieve their personal best.  NYU Winthrop personnel like each other, respect each other and take care of each other  which has created an environment that allows us to treat our patients like family. Patients sense this, and often remark about the unbelievable "caring" they experience at NYU Winthrop." Working with online statistics provider Statista, Forbes asked more than 30,000 U.S. workers to determine, on a scale of zero to 10, how likely they were to recommend their employer to someone else. Further, how did they feel about the other employers in their industry? The employees who took part in the survey were consulted anonymously through several online access panels. Their scores were analyzed using the net promoter score theory — and involved highly-selective criteria — to determine the company's eligibility and rank as one of America's Best Employers. This year's list includes 500 employers across 25 industries ranging from hospitals to corporate giants to universities and government agencies. About NYU Winthrop Hospital Founded in 1896 by a group of local physicians and concerned citizens, Long Island's first voluntary hospital is a 591-bed university-affiliated medical center and an American College of Surgeons  (ACS) Adult Level 1Trauma Center which offers a full complement of inpatient and outpatient programs and services for the newborn through the elderly in a dynamic, progressive environment. With one of the top cardiac programs in the region, NYU Winthrop Hospital holds its rightful place among the top five Transcatheter Aortic Valve Replacement (TAVR) centers in the country.  A leader and innovator in the many specialty areas, NYU Winthrop Hospital is home to the first Diabetes Education Program in New York State and was the first major teaching hospital in New York State to earn The Joint Commission's Gold Seal of Approval™ for its Advanced Inpatient Diabetes Care. Consistently recognized for quality patient care, NYU Winthrop's awards, recognitions and accreditations are many including recent national recognition for excellence in nursing from the American Nurses Credentialing Center's (ANCC) Magnet Recognition Program® – the highest recognition that a hospital can earn in the area of nursing excellence. Ever changing and growing with the diverse community it serves, NYU Winthrop Hospital is, in many ways, a unique institution, simultaneously large and small, regional as well as local. It successfully blends the progressive philosophy, sophistication and advances of a teaching and research institution with a very personal approach to patient care – an approach that has become the cornerstone of our organization. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forbes-names-nyu-winthrop-one-of-americas-best-employers-for-2017-300454739.html


Exploring the Latest Research Advancements That Are Shaping Hypertension Treatment Hypertension 2017 will include a series of forums, seminars, workshops and networking with the aim of raising awareness, promoting healthy behaviours, motivating self-care and early detection, as well as creating supportive environments for prevention and control of high blood pressure. Amsterdam, Netherlands, May 10, 2017 --( Realizing the importance to explore latest research advancements in Hypertension treatment, Cardiology Conferenceseries is organizing the 2nd International Conference on Hypertension & Healthcare, which is scheduled to be held during September 11-13, 2017 at beautiful city Amsterdam which has no shortage of beautiful landscapes and unique sites for travelers to explore. From coast to coast, the country is home to vibrant and culturally rich cities, along with incredible natural wonders. The meet is expected to provide great scope for interaction of professionals including in addition to medical & clinical experts and top-level cardiologists, professors and scientists from around the globe, on a single platform. Hypertension 2017 by Cardiology Conferenceseries has been designed in collaboration with Canadian Nutrition Society, Arrhythmia Alliance, National Association for Diabetes Care, Russian Society of Hypertension, Scandinavian Society for Atherosclerosis Research, Argentinian Society of Hypertension, Latin American Society of Hypertension, Asian Pacific Society of Hypertension, Bosnia & Herzegovina Society of Hypertension & Pakistan Hypertension League to spread the awareness about challenges in this field and how to prevent and manage hypertension. Hypertension 2017 will delight the huge gathering with a cordial theme of “New insights in diagnosis and management for hypertension” and anticipates the presence of renowned speakers including doctors, professors, scientists, research fellows, students, business professionals and many more from leading universities, companies and medical research institutions, hospitals sharing their novel researches in the arena of Cardiology, Medicine and Healthcare Major tracks summoned for the discussion include Hypertension & Stroke, Renal Hypertension, Pulmonary Hypertension, Gestational Hypertension, Pediatric Hypertension, Obesity, Hypertension Epidemiology, Diagnosis and Pathophysiology, Causative factors and risk assessment, Pharmacologic and other treatments, Nursing Management and Clinical Case Reports. Prominent speakers at the event: · Peter de Leeuw, Maastricht University Medical Center, Netherlands · Pieter Doevendans, University Medical Center Utrecht, Netherlands · Hossein Tabriziani, Loma Linda University, USA · Stamatios Lerakis, Emory Heart and Vascular Center, USA · Jose Antonio F. Ramires, University of São Paulo, Brazil · Louis Peeters, Utrecht University, Netherlands · Hans Duvekot, Erasmus University, Netherlands · Marc Spaanderman, Maastricht University, Netherlands · Valéria Paula S. Fazan, University of São Paulo, Brazil · Sokolovic Sekib, University Clinical Center Sarajevo and Medical, Bosnia and Herzegovina Hypertension 2017 runs a comprehensive programme, offering delegates: · cutting-edge clinical education · CPD & CME credits, helping delegates to prepare for revalidation · opportunities to network · Updated skills and knowledge. Receive CME credits while enjoying you in one of the Europe's most vibrant and exciting city Amsterdam, full of attractions and activities for the entire family. For more details on Hypertension 2017, please visit: http://hypertension.conferenceseries.com/ For further details contact Jessie Alison Program Manager Hypertension 2017 Email: hypertension@cardiologymeeting.com ; hypertension@cardiologyconference.org Amsterdam, Netherlands, May 10, 2017 --( PR.com )-- Hypertension, or high blood pressure, is a leading contributor to heart disease and stroke, two diseases which together account for 1 in 5 premature deaths (under age 65). In the past decade, the prevalence of hypertension has increased by 11%. Today, over 1 in 4 adults (estimated 1.8 million people) report having hypertension. Diagnosing and treating high blood pressure with lifestyle counselling and with the right medications can prevent hospital admissions, heart attacks, strokes, heart failure, and premature death. Although genetics plays a role, it is clear that lifestyle and diet are a major component. It is often a silent manifestation of underlying untreated medical, behavioural or social conditions. Education, periodic early screening and lifestyle modification significantly delay and even prevent the onset of the disease.Realizing the importance to explore latest research advancements in Hypertension treatment, Cardiology Conferenceseries is organizing the 2nd International Conference on Hypertension & Healthcare, which is scheduled to be held during September 11-13, 2017 at beautiful city Amsterdam which has no shortage of beautiful landscapes and unique sites for travelers to explore. From coast to coast, the country is home to vibrant and culturally rich cities, along with incredible natural wonders. The meet is expected to provide great scope for interaction of professionals including in addition to medical & clinical experts and top-level cardiologists, professors and scientists from around the globe, on a single platform.Hypertension 2017 by Cardiology Conferenceseries has been designed in collaboration with Canadian Nutrition Society, Arrhythmia Alliance, National Association for Diabetes Care, Russian Society of Hypertension, Scandinavian Society for Atherosclerosis Research, Argentinian Society of Hypertension, Latin American Society of Hypertension, Asian Pacific Society of Hypertension, Bosnia & Herzegovina Society of Hypertension & Pakistan Hypertension League to spread the awareness about challenges in this field and how to prevent and manage hypertension.Hypertension 2017 will delight the huge gathering with a cordial theme of “New insights in diagnosis and management for hypertension” and anticipates the presence of renowned speakers including doctors, professors, scientists, research fellows, students, business professionals and many more from leading universities, companies and medical research institutions, hospitals sharing their novel researches in the arena of Cardiology, Medicine and HealthcareMajor tracks summoned for the discussion include Hypertension & Stroke, Renal Hypertension, Pulmonary Hypertension, Gestational Hypertension, Pediatric Hypertension, Obesity, Hypertension Epidemiology, Diagnosis and Pathophysiology, Causative factors and risk assessment, Pharmacologic and other treatments, Nursing Management and Clinical Case Reports.Prominent speakers at the event:· Peter de Leeuw, Maastricht University Medical Center, Netherlands· Pieter Doevendans, University Medical Center Utrecht, Netherlands· Hossein Tabriziani, Loma Linda University, USA· Stamatios Lerakis, Emory Heart and Vascular Center, USA· Jose Antonio F. Ramires, University of São Paulo, Brazil· Louis Peeters, Utrecht University, Netherlands· Hans Duvekot, Erasmus University, Netherlands· Marc Spaanderman, Maastricht University, Netherlands· Valéria Paula S. Fazan, University of São Paulo, Brazil· Sokolovic Sekib, University Clinical Center Sarajevo and Medical, Bosnia and HerzegovinaHypertension 2017 runs a comprehensive programme, offering delegates:· cutting-edge clinical education· CPD & CME credits, helping delegates to prepare for revalidation· opportunities to network· Updated skills and knowledge.Receive CME credits while enjoying you in one of the Europe's most vibrant and exciting city Amsterdam, full of attractions and activities for the entire family.For more details on Hypertension 2017, please visit: http://hypertension.conferenceseries.com/For further details contactJessie AlisonProgram ManagerHypertension 2017Email: hypertension@cardiologymeeting.com ; hypertension@cardiologyconference.org Click here to view the list of recent Press Releases from Cardiology Conference Series


News Article | May 22, 2017
Site: www.prnewswire.com

Joining the Board of Managers are Joseph Mosele, Vice President, Business Development, AT&T Business Solutions; James Parshall, Director, Software Device Solutions, Eli Lilly and Company; Michael Spedding, Global CEO, Ipsos Healthcare; Jeremy Malecha, Vice President, Global Product Management, Healthcare Informatics, ResMed; and Alex Gao, Head of Digital Health Lab, Samsung Research America. PCHAlliance also welcomed six additional members: Propel Health, Voluntis, Rooi Digital, Ingram Micro, Danish Health Data Authority and HAP Innovations. "Working closely with the Board, PCHAlliance published a refined strategy in 2016. This has encouraged many of the  PCHAlliance members to become more deeply involved through Working Groups, strategic initiatives and events," added Horst Merkle, Chair, PCHAlliance Board of Managers, and Director, Digital Solutions, Roche Diabetes Care. "We are truly becoming a platform that is representative of a highly diverse and growing personal connected health ecosystem. Thank you to the Board for their vision and support, as we reimagined the organization to best suit the needs of our membership and realize the full potential of personal connected health around the world." PCHAlliance's goal is to help people make health and wellness an effortless part of daily life. The Alliance is convening the global personal connected health community -- technology companies, healthcare providers, payers, governments and the public -- to accelerate the technical, business, policy and social initiatives necessary to advance the field. PCHAlliance is developing and promoting technical standards, facilitating collaboration, convening conferences, sharing research and advocating policy to help drive personal connected health forward. The Personal Connected Health Alliance (PCHAlliance) aims to make health and wellness an effortless part of daily life. The PCHAlliance, a non-profit organization formed by HIMSS, believes that health is personal and extends beyond healthcare. The Alliance mobilizes a coalition of stakeholders to realize the full potential of personal connected health. PCHAlliance members are a vibrant ecosystem of technology and life sciences industry icons and innovative, early stage companies along with governments, academic institutions, and associations from around the world. To support its vision, PCHAlliance convenes the global personal connected health community at the annual Connected Health Conference, the premier international event for the exchange of research, evidence, ideas, innovations and opportunities in personal connected health. The Alliance publishes and promotes adoption of the Continua Design Guidelines. Continua is recognized by the International Telecommunication Union (ITU) as the international standard for safe, secure, and reliable exchange of data to and from personal health devices. PCHAlliance accelerates technical, business, policy and social strategies necessary to advance personal connected health through its flagship Academy for Healthy Longevity to promote lifelong health and wellness. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/personal-connected-health-alliance-welcomes-a-dozen-new-members-300461399.html


"Living with diabetes can be challenging and complicated which is why we are excited to launch the new Accu-Chek Guide System combining simple advancements and state-of-the-art technology to provide a better testing experience," said Brad Moore, Head of Roche Diabetes Care, North America. "Additionally, as a company that operates and manufactures its test strips in the US, we recognize that in addressing the needs of the millions of people in this country living with diabetes, it is equally important to provide a solution that ensures all patients receive better quality of care without cost being a barrier." The Accu-Chek Guide System, which is now available at most pharmacies, also automatically tracks results to the Accu-Chek® Connect diabetes management app and online portal eliminating the need for a logbook as well as a test strip ejector button, allowing fast, easy, and hygienic strip disposal. To utilize the savings program patients can hand the SimplePay card to their pharmacist along with the Accu-Chek Guide meter and strip prescription to start saving. For more information and to download the free SimplePay Savings card visit accu-chek.com/guide. Survey Methodology The Roche Diabetes Care Survey was conducted by Wakefield Research (www.wakefieldresearch.com) among 500 U.S. adults with diabetes, between April 11th and April 19th, 2017, using an email invitation and an online survey. Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 4.4 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample. About Accu-Chek® Guide The Accu-Chek® Guide system is Roche Diabetes Care's new generation of wireless blood glucose monitoring (BGM) systems, designed to respond to previously unmet needs of people with diabetes and their healthcare professionals. As such, it offers new features such as the exclusive, SmartPack TM spill-resistant strip vial and new test strip chemistry and design. Moreover, the system provides Bluetooth® low energy connectivity to the Accu-Chek® Connect diabetes management app and online portal and offers reliable test results that exceed the new global ISO 15197:2013/EN ISO 15197:2015 accuracy standards2,3. About Roche Diabetes Care Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek® brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients' condition in an optimal way. Today, the Accu-Chek® portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek® brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information please visit www.accu-chek.com About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. For more information please contact: Anne Gill Head of Communications, Diabetes Care North America Indianapolis, IN Phone: 317.521.0500 anne.gill@roche.com 1 95% of the measured glucose results shall fall within ±10 mg/dL of lab reference value for blood glucose concentrations <100 mg/dL and within 10% for blood glucose concentrations ≥100 mg/dL. Data on file 2 Brazg RL, Klaff LJ, Sussmann, AM, Parkin: Accu-Chek Guide Blood Glucose Monitoring System Exceeds International Accuracy Standards, Journal of Diabetes Science and Technology 1–2, DOI: 10.1177/1932296816652902 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roche-diabetes-care-introduces-blood-glucose-meter-and-savings-program-designed-to-help-the-over-29-million-people-living-with-diabetes-300462947.html


- 409 MILLION GLUCOSE MEASUREMENTS FROM MORE THAN 50,000 FREESTYLE LIBRE USERS IN EUROPE SHOW PEOPLE MONITORED THEIR GLUCOSE LEVELS ON AVERAGE 16 TIMES PER DAY - 86 MILLION HOURS OF MONITORING DEMONSTRATE THAT A HIGHER NUMBER OF FREESTYLE LIBRE SCANS IS ASSOCIATED WITH BETTER DIABETES OUTCOMES INCLUDING A REDUCTION IN HYPOGLYCEMIA PARIS, Feb. 16, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the results of real-world use data[1] showing that people who scan more frequently using Abbott′s FreeStyle® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels. According to the data, more than 50,000 people with diabetes using the FreeStyle Libre system checked their glucose levels an average of 16 times per day—which is three times more than the minimum recommended U.S.[2] and European[3] guidelines for testing with the traditional fingerstick technique. The data show that higher rates of scanning with the FreeStyle Libre system were found to be strongly associated with improved glucose control. "There is now substantial evidence from both real-world usage and clinical studies that reaffirms the powerful impact of FreeStyle Libre," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "FreeStyle Libre is changing how diabetes has been managed for decades, with one simple swipe. Most importantly, we're doing that by empowering patients with the information that they need to take action themselves, helping people living with diabetes live fuller, healthier lives." Abbott′s FreeStyle Libre system consists of a small, round sensor worn on the back of the upper arm for up to 14 days, which measures glucose every minute in interstitial fluid through a small filament that is inserted just under the skin and held in place with a small adhesive pad. A reader is scanned over the sensor to get a glucose result painlessly[4] in less than one second. The real-world data findings were presented today at the Advanced Technologies and Treatment for Diabetes (ATTD) congress in Paris. The data show a strong link between real-world use of FreeStyle Libre system and glucose control. The full data set was generated from 50,831 readers, which were used to scan 279,446 sensors. This constituted 409.4 million glucose measurements, 86.4 million monitoring hours and 63.8 million scans – representing more than 50,000 FreeStyle Libre users across the Europe region. Key findings of the real-world data of the FreeStyle Libre system: Empowering Patients with Actionable Information According to a published report in Patient Preference and Adherence[5] people test with traditional self-monitoring methods (pricking a finger with a lancet to get a blood sample) less than three times per day, which falls short of U.S.[2] and European[3] guidelines that recommend four to eight self-tests per day. People with diabetes cite the biggest obstacle to more frequent monitoring is the pain and hassle of routine fingersticks[5]. But when people with diabetes don't have a clear picture of their glucose levels from regular monitoring, complications such as hypoglycemia can become life-threatening and require hospitalization, which can lead to a significant increase in healthcare costs. Abbott's FreeStyle Libre system, which was introduced in Europe in 2014, removes the need for routine fingersticks[6],[7] — and the pain and hassles that come along with them[8]. In addition, FreeStyle Libre system is factory calibrated—meaning that it does not require a fingerstick test for calibration (a test requiring a blood sample to reset a system's accuracy) unlike other continuous glucose monitoring systems, which require two or more fingersticks per day to remain accurate. "My experience with FreeStyle Libre through daily clinical practice and research studies has been very positive," says Ramzi Ajjan, M.D., University of Leeds, U.K. "Patients report that the system helped them gain a better understanding of their glycaemia by enabling multiple daily glucose checks discreetly and conveniently. The system's painless nature of glucose testing are praised by patients with one commenting to me, 'you saved my fingers.' The real-world data further confirms that patients are checking glucose more frequently, up to 16 times per day on average, which is cumbersome to maintain with the conventional fingerstick method. With comprehensive glucose data, patients now have access to more meaningful information key for optimizing their glycaemia control." Real-World Usage Supports Randomized Controlled Data of FreeStyle Libre The new real-world data presented at ATTD further support the conclusions of the randomized controlled clinical studies conducted by Abbott with the FreeStyle Libre system including the IMPACT study[9] published in The Lancet in September 2016. In 2014, Abbott launched the FreeStyle Libre system in several countries in Europe. Currently, FreeStyle Libre system is available in more than 30 countries around the globe and is being used by more than 250,000 people living with diabetes. In the U.S., the FreeStyle Libre system is currently under review by the U.S. Food and Drug Administration[10]. About the Data De-identified data was collected over a period of 18 months when FreeStyle Libre readers were connected to the PC-based software with an active internet connection. All information was aggregated. No personal data was utilized or shared. About Abbott′s FreeStyle Libre System Abbott′s FreeStyle Libre system consists of a small, round sensor—approximately the size of two stacked U.S. quarters—worn on the back of the upper arm for up to 14 days, which measures glucose every minute in interstitial fluid through a small (5mm long, 0.4mm wide) filament that is inserted just under the skin and held in place with a small adhesive pad. A reader is scanned over the sensor to get a glucose result painlessly[4] in less than one second. Each scan displays a real-time glucose result, a historical trend and the direction the glucose is heading. The FreeStyle Libre system generates an Ambulatory Glucose Profile (AGP) that provides a visual snapshot of glucose levels, trends and patterns over time. About Abbott: At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @FreeStyleDiabet, @AbbottNews and @AbbottGlobal.


BOSTON--(BUSINESS WIRE)--T1D Exchange, a nonprofit organization accelerating research to improve outcomes in type 1 diabetes, today published a major research study in Diabetes Care that confirms the use of Continuous Glucose Monitoring (CGM) without regular use of confirmatory Blood Glucose Measurements (BGM) is safe and effective. For years, patients with type 1 diabetes have relied on blood glucose monitoring (BGM), widely known as the finger prick method, to measure their blood glucose levels many times each day and make insulin dosing decisions based on this information. CGM monitors are small wearable devices that automatically capture real-time glucose measures via a sensor that is inserted under the skin and transmits the information wirelessly to a monitoring and display device. CGM systems can detect and alert patients when they may be at risk of hyperglycemia (high blood glucose) or hypoglycemia (low blood glucose), both of which require intervention to avoid more dangerous complications. Over the past few years, adoption of CGM to monitor blood glucose levels has widely grown, according to T1D Exchange’s Clinical Registry which has health data on 32,000 patients with type 1 diabetes. Specifically, adoption of CGM in the registry cohort has grown from 7% CGM use overall (in analysis completed in 2010-2012) to 21% CGM use overall (in analysis completed during 2014-2015). The T1D Exchange Replace-BG research study was conceived to better understand how CGM systems are used by patients, how they affect their health outcomes and to build evidence that will be required to support access to and reimbursement of CGM systems. This research is also critical to advance the field of automated insulin delivery. Automated insulin delivery (AID), commonly referred to the “artificial pancreas,” is the evolution of current diabetes management devices to an integrated system incorporating insulin pumps, algorithms and CGM technology that will allow insulin delivery with little or no input from the patient – thereby relieving a significant burden while improving outcomes. As the first major study of its kind, T1D Exchange coordinated the multi-center study through its clinic network and enrolled 226 adults with type 1 diabetes. All study participants were provided with a Dexcom’s G4 Continuous Glucose Monitoring System with an enhanced algorithm, which was used for the 6-month duration of the study. Participants were split into two study arms: 149 participants dosed their insulin based on the CGM reading alone without first confirming with a blood glucose meter measurement and 77 were required to confirm the CGM reading with a blood glucose measurement before dosing insulin. Among the major findings of the study is the confirmation there was no difference in outcomes for those using only CGM and those using both CGM and BGM. “This study is an important step to support regulatory pathways for the automation of insulin delivery for people with type 1 diabetes,” says Dana Ball, executive director and co-founder of T1D Exchange. “These data are supportive of the recent FDA decision to approve the Dexcom G5 indication for insulin dosing and removes a key obstacle that has prevented reimbursement of CGM by Medicare.” "We are grateful that organizations such as T1D Exchange recognize the need to build evidence around the safety and efficacy of CGM use in treatment decisions,” says Kevin Sayer, president and chief executive officer of Dexcom. “We hope results from this study and the recent FDA decision to expand the indication of the Dexcom G5 system will diminish the hassle and pain of finger stick testing and expand access to CGM technology—ultimately leading to improved control for people with diabetes." This study was funded by The Leona M. and Harry B. Helmsley Charitable Trust and CGMs were donated by Dexcom. The research is being presented today at Advanced Technologies and Treatments for Diabetes (ATTD) in Paris, France by principal investigators from the Jaeb Center for Health Research in Tampa, FL, Katrina J. Ruedy, MSPH, and Roy W. Beck M.D., Ph.D., Director, T1D Exchange Clinic Coordinating Center. “As a practicing endocrinologist, I typically advise my patients who use CGM technology to make treatment decisions based on a BGM reading; however, many of my patients often use CGM readings to make decisions about insulin doses,” stated Grazia Aleppo, MD, Northwestern University and lead author of the study. “The results of this study assures clinicians that patients using CGM for treatment decisions is as safe and effective as BGM.” About T1D Exchange T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model offers researchers access to aggregated clinical, biological, patient-reported outcomes and electronic health record data, all while fostering collaboration among patients, physicians, researchers and industry. Our model is multi-faceted and complex, but our goal is simple: to tangibly improve outcomes for people with type 1 diabetes as fast as humanly possible.


Research and Markets has announced the addition of the "Infusion Pumps - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Infusion Pumps in US$ by the following Product Segments: The report profiles 52 companies including many key and niche players such as: - Infusion Pumps: An Alternate Drug Delivery Option - Current and Future Analysis - Developed Economies Dominate Infusion Pumps Market - Asia-Pacific: The Fastest Growing Market for Infusion Pumps - Analysis by Product Segments - Ambulatory Infusion Pumps - Enteral Feeding Pumps - Insulin Infusion Pumps - Large Volume Infusion Pumps - PCA Infusion Pumps - Syringe Infusion Pumps - Infusion Errors & Technology Defenses Developed Over the Years - Rise in Incidence of Chronic Diseases Fuels Infusion Pumps Demand - The Diabetes Epidemic - Untapped Potential for Insulin Pumps - Global Diabetes Expenditure: Opportunity Indicator for Insulin Pumps Market - Cancer Pain Offers Potential Opportunities for Pain Management Pumps - Infusion Pumps - A Highly Consolidated Market - Insulin Pumps Market - Competition Intensifies - Comparison of Select Durable Insulin Pumps by Manufacturer - Medtronic Banks on New Solutions and Distribution Expansion to Retain Dominance - J&J's OneTouch Via - A Discrete Solution for On-Demand Insulin - Ypsomed Eyes Brighter Prospects with YpsoPump - Medtrum - A New Entrant with a Strong Product; Threatening to Take the Market by Storm - Competitive Landscape in the Insulin Patch Pump Market - OmniPod Benefits from Lack of Close Competition in its League - Insulet Focuses on Advances in Technology and Services to Gain Market Share - Cellnovo's Patch Pump Combines Functionality and Cost- Effectiveness - V-Go - An Affordable Patch Pump for Type II Diabetics - Expiry of Warranty Provides New Opportunities to Insulin Pump Makers - Customer Satisfaction: Crucial to Stay Competitive - Enteral Feeding Devices: An Intensely Competitive Market - Multinationals Target Emerging Markets - The New Hotspots for Growth - Infusion Errors: A Key Driving Force for Newer Technologies - Manufacturers Focus on Interoperability with EMR Systems - Security of Wireless Medical Device - A Vital Factor - Shift from Hospital Environments to Alternative-Sites/ Home Settings Drives the market for Home Infusion Pumps - Product Complexity Thwarts ROI on Devices - Smart Pump Technology: A Major Growth Driver - Smart Pumps with Innovative Features - Improving Functionality for Enhanced Patient Compliance - Maintaining Smartness Quotient of Smart Infusion Pumps - Product Bundling: A Double Whammy Success - Analgesia Infusion Pumps Continue to Register Favorable Growth - Disposable Ambulatory Infusion Pumps Market Exhibits Notable Stride Forward - Enteral Feeding Pumps Market Overview - Replacements Offer Potential Growth Opportunities - Preference for Enteral Nutrition over Parenteral Nutrition Bodes Well - Advantages and Disadvantages of Enteral Nutrition over Parenteral Nutrition - Enteral Nutrition Therapy in Treating Adult Malnutrition Offers Growth Opportunities - Home Enteral Therapy to Boost Demand for Enteral Feeding Devices - Insulin Pumps - Designed for Optimum Disease Management - The Rise of Smart Pumps - Manufacturers Eye Type II Diabetes Market - Implantable Insulin Pumps - The Next Generation of Insulin Pumps - Patch Pumps Gain Manufacturer Attention - Insulin Pump Training - An Important Driver - Complicated Insulin Pump Software Makes Pump Use Difficult for the Aged - Competition from Other Insulin Delivery Technologies Continues - Maturity Hits Volumetric Infusion Pumps Market - Equipment Recalls Thwarts Growth Prospects - Stringent Safety Regulations Impede Time-to-Market - Look into Select Technology Advancements - Ivenix Develops Next-Generation Infusion Management Platform - Innovfusion Develops Advanced Infusion Pumps to Provide Relief from Labor Pain - Summit Medical's Low-Cost Portable Infusion Pumps Improve Patient Care - Product Malfunctioning Erodes Penetration of Implantable Infusion Pumps Rise in Healthcare Spending in Developing Nations Bode Well for the Market Aging Population: A Strong Growth Driver Global Aging Population Statistics Opportunity Indicators Rise in Incidence of Cancer and Central Nervous System Diseases Foster Growth World Cancer Statistics: Incidence and Mortality Data Diabetes Incidence and Prevalence Global Diabetic Statistics Opportunity Indicators Alarming Rise in Obesity A Business Case for Diabetes Care Rise in HIV Prevalence Provides Ample Growth Opportunities Global HIV Statistics Opportunity Indicators for Enteral Feeding Devices - FDA Announces Initiative to Address Safety Concerns Related to Infusion Pumps - FDA Announces a New Mandate for Manufacturing Companies - Regulations Promote Adoption of Premium-Priced Safety Devices - ISO 80369 Standards for Small-Bore Connector - ENFit - The New ISO Standard Enteral Feeding Connecting System - Infusion Pumps: A Definition - Types of Infusion Pumps - Ambulatory Infusion Pumps - Non-Electronic Ambulatory Infusion Pumps - Advantages & Disadvantages of Non-Electronic Pumps - Electronic Ambulatory Infusion Pumps - Nerve Block Infusion Pumps - Enteral Feeding Pumps - Insulin Infusion Pumps - Large Volume Infusion Pumps - Pump Architecture of Volumetric Pumps - Classification by End-Use Application - Volumetric Pumps used in Acute Care Settings - Volumetric Pumps used in Alternate Care Settings - Patient Controlled Analgesic (PCA) Pumps - Syringe Infusion Pumps - Low-End and High-End Syringe Pumps - Implantable Infusion Pumps - Programmable Implantable Infusion Pumps - Constant Flow Implantable Infusion Pumps - Approved Applications of Implantable Infusion Pumps - Common Safety Features Available In Most Infusion Pumps - Key Problems Reported with Infusion Pumps - User Interface Issues - Software Issues - Alarm Errors - Damaged Components - Battery Failures - Fire, Shocks, Sparks or Charring - Intelligraphics Enters into Collaboration with Ivenixto Develop Intelligent Infusion Pump Platform - Smiths Medical Introduces New Software Version for use with Medfusion® 4000 wireless syringe pumps - Caesarea Medical Announces Launch of its latest Dual Channel Infusion Pump - Medtronic Launches MiniMed® 630G System - Hospira Introduces LifeCare PCA 7.0 infusion pump with EMR Connectivity - Smiths Medical Launches New CADD®-Solis Pump - Animas Bags FDA Approval for Animas® Vibe® Insulin Pump and Continuous Glucose Monitoring System - Medtronic Rolls Out MiniMed 640G Insulin Pump - B. Braun Medical Secures FDA Approval for Infusomat® Space Pump - Zyno Medical Gains CE Mark Approval for Z-800 Infusion Pump System - Hospira Receives FDA Clearance for Plum 360 Infusion System - BioLeonhardt Develops Stem Cell Pump - Animas Rolls Out Animas® Vibe Insulin Pump with Latest Dexcom CGM Technology - Baxter Gets FDA Clearance for SIGMA Spectrum Infusion Pump with Master Drug Library - Animas Bags CE Mark Approval for Animas® Vibe Insulin Pump and Dexcom G4 PLATINUM CGM System - Animas Secures FDA Approval for Animas® Vibe Insulin Pump and Continuous Glucose Monitoring System Omnicell and Hospira Collaborate for System Interoperability BD Enters into Collaboration with JDRF to Develop Extended Wear Innovations for Insulin Infusion Delivery Teleflex Signs Group Purchasing Agreement with Premier Inc. for Implantable Infusion Ports ICU Medical to Acquire Pfizer's Infusion Therapy Business Zyno Medical Receives FDA 510(k) Clearance for Nimbus II Ambulatory Infusion System InfuSystem to Acquire Infusion Pump Assets from InfusAID, LLC Medtronic to Manufacture and Deploy Advanced Diabetes Therapies in Chengdu, China Pfizer Considers Sale of the Infusion Pump Business Pfizer Acquires Hospira InfuSystem Completes Acquisition of Ciscura Becton Dickinson Takes Over CareFusion Hospira Inks Agreement with Cerner for Developing Infusion Pump Information Platform Animas Partners with Tidepool Medtronic Partners with BD to Develop New Insulin Pump with BD FlowSmart Technology Fresenius Kabi Inks Agreement with Amerinet Hospira Faces Class I Recall of GemStar Infusion System - Animas Corporation (USA) - Baxter International Inc. (USA) - B. Braun Melsungen AG (Germany) - Becton, Dickinson and Company (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fresenius SE & Co. KGaA (Germany) - Halyard Health, Inc. (USA) - Hospira, Inc. (USA) - ICU Medical, Inc. (USA) - Insulet Corporation (USA) - Medtronic, PLC (Ireland) - Moog, Inc. (USA) - Smiths Medical (USA) - Sooil Development Co. Ltd. (Korea) - Tandem Diabetes Care, Inc. (USA) - Teleflex Incorporated (USA) - Terumo Corporation (Japan) - The United States - Japan - Europe - France - Germany - The United Kingdom - Rest of Europe - Asia-Pacific (Excluding Japan) - Middle East - Latin America For more information about this report visit http://www.researchandmarkets.com/research/cq3cv2/infusion_pumps


- Users of the mySugr app will be able to automatically upload blood glucose data from the next-generation Accu-Chek blood glucose meters, the Accu-Chek Guide and Accu-Chek Instant systems. - Users will benefit from enhanced capabilities  to share diabetes data with their healthcare providers and caregivers. - Healthcare providers can utilise existing Roche tools to make better therapy decisions in less time and improve their collaboration with patients who are users of the mySugr app. BASEL, Switzerland, Feb. 15, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expansion of its partnership with mySugr, a digital diabetes service company providing apps to help reduce the burden for people with diabetes in managing their chronic condition. The integration of Roche's next generation of Accu-Chek blood glucose meters, the Accu-Chek Guide and the Accu-Chek Instant systems with the mySugr app allows users to benefit from the partnership in different ways: The ability to automatically upload blood glucose data into the mySugr app as well as the facilitated data sharing with healthcare professionals and caregivers via the cloud-based Accu-Chek Connect Online and emminens eConecta platforms. The partnership with mySugr supports both companies in broadening access to innovative digital health solutions. "With this expanded partnership we will continue to offer latest innovations to our customers that will empower them to seamlessly integrate therapy management into their everyday lives, so they have less to think and worry about," states Marcel Gmuender, Global Head of Roche Diabetes Care. "Digital health solutions have proven to help manage diabetes-related data more effectively. This makes data more meaningful1 and can ultimately lead to better therapy outcomes." The expanded agreement is effective as of today. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. About Roche Diabetes Care Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – leading to an improved medical outcome. For more information please visit www.accu-chek.com All trademarks used or mentioned in this release are protected by law. References 1. Hinnen D, Buskirk A, Lyden M, Amstutz L, Hunter T, Parkin CG, Wagner R. Use of diabetes data management software reports by health care providers, patients with diabetes, and caregivers improves accuracy and efficiency of data analysis and interpretation compared with traditional logbook data: first results from the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES). J Diabetes Sci Technol. Pub online 2 Nov 2014. DOI: 10.1177/1932296814557188.


ARLINGTON, Tenn.--(BUSINESS WIRE)--MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced that The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.1 It has been reported that approximately 20% of patients are not satisfied with the outcome of their total knee replacement as a result of residual pain and functional issues often attributed to implant design.2 MicroPort’s Medial-Pivot Knee System is uniquely designed to restore stability and normal knee kinematics to deliver reproducible outcomes that can improve function and drive patient satisfaction. “I am in my third year of using the Evolution® Medial-Pivot Knee System and this publication validates the results that I have seen in my practice,” says David Backstein, MD, MEd, FRCSC, Head of Orthopaedic Surgery at Mount Sinai Hospital in Toronto, Ontario. “In my experience, the functional outcomes for patients treated with this system have certainly been superior than the systems I’ve used in the past and patients have fewer complaints. When I see them at six or eight weeks follow-up, they're at a different stage of recovery than I was seeing previously with traditional implant designs. I've been exceptionally happy with the results and feel comfortable knowing I am implanting a prosthesis with 98.8% survivorship at 17 years.” The paper, titled, A Long Term Clinical Outcome of the Medial Pivot Knee Arthroplasty System was authored by George A Macheras et al. from the “KAT” General Hospital, Athens, Greece. In the study, 325 patients with knee osteoarthritis underwent Total Knee Arthroplasty (TKA) using the Medial-Pivot prosthesis. All patients showed a statistically significant improvement in the Knee Society clinical rating system, Western Ontario and McMaster Universities Osteoarthritis Index, and Oxford knee score. The majority of patients (94%) were able to perform age-appropriate activities with average knee flexion of 120° and 98% of patients reported relief of pain to be excellent, very good or good. Additionally, survival analysis showed a cumulative success rate of 98.8% at 17 years. About MicroPort Orthopedics Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/. About MicroPort MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 20 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com. Forward-Looking Statements Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China. This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever. 1. George A. Macheras et al. “A long term clinical outcome of the Medial Pivot Knee Arthroplasty System.” The Knee Journal, Published: January 29, 2017. 2. Thambiah, Matthew Dhanaraj et al. “Patient Satisfaction after Total Knee Arthroplasty: An Asian Perspective.” Singapore Medical Journal 56.5 (2015): 259–263. PMC. Web. 22 Feb. 2017.

Loading Diabetes Care collaborators
Loading Diabetes Care collaborators